Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Next-gen assays for better cancer diagnosis
July 2017
SHARING OPTIONS:

IRVINE, Calif. & HERSTAL, Belgium—A new agreement is underway between MDxHealth SA and the faculty of Health, Medicine and Life Sciences/School for Oncology and Developmental Biology (GROW) at Maastricht University that expands an existing research collaboration. The agreement focuses on the development of next-generation epigenetic-based assays for the diagnosis, staging and treatment of cancer patients. The assays will be centered on sample-in and result-out-based platforms, and the technology would also be applied to MDxHealth’s liquid biopsy tests.
 
“GROW at Maastricht University are true visionaries and we are fortunate to have such a longstanding and collaborative relationship,” said Dr. Jan Groen, CEO of MDxHealth. “The development of next-generation liquid biopsy diagnostics for oncology will be game-changing and help physicians manage their patients faster and more effectively.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.